Prostate drug boosts PFS in metastatic disease
'This is very different from chemotherapy,' study author says
5th June 2019
In men with metastatic castration-sensitive prostate cancer, adding apalutamide to conventional androgen-deprivation therapy can produce a 52% increase in the rate of radiographic progression-free survival, researchers report.
In their first interim analysis of the international TITAN study, funded by the manufacturer of the drug, a 24-month progression-free survival (PFS) rate of 68% was achieved in the apalutamide arms compared with 49% for placebo therapy in addition to androgen-deprivation therapy, at a median follow-up of 23 months.
"The effect of apalutamide
